Cited by 247Lung Cancer Treatments and MutationsBrain Metastases and TreatmentLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Open access

Goss, G., Tsai, C.-M., Shepherd, F.A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., Cantarini, M., Johnson, M., Mitsudomi, T., Jänne, P.A., Yang, J.C.-H.·2018·Annals of Oncology

DOI 10.1093/annonc/mdx820

Open this paper in CoChat — free account

Abstract

Background: Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic efficacy in patients with CNS metastases, and early clinical evidence shows efficacy in the CNS. To evaluate osimertinib activity further, we present a pre-specified subgroup analysis of CNS response using pooled data from two phase II studies: AURA extension (NCT01802632) and AURA2 (NCT02094261). Patients and methods: Patients with T790M-positive advanced NSCLC, who had progressed following prior epidermal growth factor receptor-tyrosine kinase inhibitor treatment, received osimertinib 80 mg od (n = 411). Patients with stable, asymptomatic CNS metastases were eligible for enrolment; prior CNS treatment was allowed. Patients with ≥1 measurable CNS lesion (per RECIST 1.1) on baseline brain scan by blinded independent central neuroradiology review (BICR) were included in the evaluable for CNS response set (cEFR). The primary outcome for this CNS analysis was CNS objective response rate (ORR) by BICR; secondary outcomes included CNS duration of response, disease control rate (DCR) and progression-free survival (PFS). Results: Of 128 patients with CNS metastases on baseline brain scans, 50 were included in the cEFR. Confirmed CNS ORR and DCR were 54% [27/50; 95% confidence interval (CI) 39-68] and 92% (46/50; 95% CI 81-98), respectively. CNS response was observed regardless of prior radiotherapy to the brain. Median CNS duration of response (22% maturity) was not reached (range, 1-15 months); at 9 months, 75% (95% CI 53-88) of patients were estimated to remain in response. Median follow-up for CNS PFS was 11 months; median CNS PFS was not reached (95% CI, 7, not calculable). The safety profile observed in the cEFR was consistent with the overall patient population. Conclusions: Osimertinib demonstrated clinically meaningful efficacy against CNS metastases, with a high DCR, encouraging ORR, and safety profile consistent with that reported previously. ClinicalTrials.gov number: NCT01802632; NCT02094261.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx820

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citation
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citation
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citation
Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Mulvenna, P., Nankivell, M. G., Barton, R., Finn, C. F., Wilson, P., McColl, E., MOORE, B. J., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 723
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G. D., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Lee, J. S., Chang, G., Crinò, L., Satouchi, M., Chu, Q. S.-C., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 654
Self-citation
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Neurocognitive Function of Patients with Brain Metastasis Who Received Either Whole Brain Radiotherapy Plus Stereotactic Radiosurgery or Radiosurgery Alone
Aoyama, H., Tago, M., Kato, N., Toyoda, T., Kenjyo, M., Hirota, S., Shioura, H., Inomata, T., Kunieda, E., Hayakawa, K., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.03.048 · Cited by 542

Flagged first, then by citations

Show all 27 references

Research works printed but not linked: 1

Yang, 2017, Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component, J Clin Oncol, 35, 1288, 10.1200/JCO.2016.70.3223 · DOI · Paper page

Sorted by citations

Items 101–200 of 247

An Insight into Molecular Targets of Breast Cancer Brain Metastasis
Kaleem, M., Dalhat, M. H., Azmi, L., Asar, T. O., Ahmad, W., Alghanmi, M. S., Almostadi, A., Zughaibi, T. A., & Tabrez, S. S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911687 · Cited by 23
Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis
Xing, P., Mu, Y., Hao, X., Wang, Y.-Q., & Li, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02071-5 · Cited by 24
EGFR inhibition in NSCLC: New findings…. and opened questions?
Passiglia, F., Listì, A., Castiglia, M., Perez, A., Rizzo, S., Bazan, V., & Russo, A. D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.009 · Cited by 22
Reduced sensitivity for EGFR T790M mutations using the Idylla EGFR Mutation Test
Lee, E., Jones, V. M., Topkas, E., & Harraway, J. R. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206527 · Cited by 22
EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
Liu, B., Liu, H., Ma, Y., Ding, Q., Zhang, M., Liu, X., & Liu, M. (2021) · Cancer Medicine · doi:10.1002/cam4.4192 · Cited by 20
Osimertinib for patients with EGFR T790M mutation-positive non–small-cell lung cancer and a poor performance status
Nakashima, K., Kimura, M., Akamatsu, H., Daga, H., Imai, H., Taira, T., Ko, R., Hisamatsu, Y., Nishino, K., Sugimoto, T., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz041 · Cited by 21
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
Liu, X., Hong, L., Nilsson, M., Hubert, S. M., Wu, S., Rinsurongkawong, W., Lewis, J., Spelman, A., Roth, J., Swisher, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.023 · Cited by 20
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)
Fukui, T., Mamesaya, N., Takahashi, T., Kishi, K., Yoshizawa, T., Tokito, T., Azuma, K., Morikawa, K., Igawa, S., Okuma, Y., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.027 · Cited by 20
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Tsubata, Y., Watanabe, K., Saito, R., Nakamura, A., Yoshioka, H., Morita, M., Honda, R., Kanaji, N., Ohizumi, S., Jingu, D., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02043-2 · Cited by 18
Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review
Wang, N., Zhang, Y., Mi, Y., Deng, H., Chen, G., Tang, Z., Mao, J., Cui, S., Zhang, Y., & Wang, L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-605 · Cited by 18
Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
Cao, Y., Qiu, X., Xiao, G., Hu, H., & Lin, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221575 · Cited by 18
The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
Gu, W., Liu, P., Tang, J., Lai, J., Wang, S., Zhang, J., Xu, J., Deng, J., Yu, F., Shi, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288468 · Cited by 18
Targeting Molecular Pathways in Intracranial Metastatic Disease
Venur, V. A., Cohen, J. V., & Brastianos, P. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00099 · Cited by 18
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
Shu, Y., Ding, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920479 · Cited by 19
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
Lee, J., Piotrowska, Z., Soo, R. A., Cho, B. C., & Lim, S. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221144099 · Cited by 17
Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
Jia, C., Xu, Q., Zhao, L., Kong, F., & Jia, Y. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101832 · Cited by 17
Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer
Jiang, S. X., Walton, R. N., Hueniken, K., Baek, J., McCartney, A., Labbé, C., Smith, E. C., Chan, S. W. S., Chen, R., Brown, C., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2603 · Cited by 17
Self-citation
The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
Wang, F., & Zhou, Q. H. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.007 · Cited by 16
Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
Chen, L., Zhou, Y., Gan, C., Wang, X., Liu, Y., Dong, C., He, R., & Yang, J. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2069254 · Cited by 17
Self-citation
Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
Hu, C., Wu, S., Deng, R., Wu, Y., Pan, Y., Shu, L., & Wu, F. (2022) · Cancer Medicine · doi:10.1002/cam4.4894 · Cited by 16
Emerging drugs for EGFR-mutated non-small cell lung cancer
Sukrithan, V., Deng, L., Barbaro, A., & Cheng, H. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1558203 · Cited by 16
Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
Carlo, E. D., Bertoli, E., Conte, A. D., Stanzione, B., Berto, E., Revelant, A., Spina, M., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126477 · Cited by 15
First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
Tatineni, V., O'Shea, P. J., Ozair, A., Khosla, A. A., Saxena, S., Rauf, Y., Jia, X., Murphy, E. S., Chao, S. T., Suh, J. H., et al. (2023) · Cancers · doi:10.3390/cancers15082382 · Cited by 16
Determination of intracellular anlotinib, osimertinib, afatinib and gefitinib accumulations in human brain microvascular endothelial cells by liquid chromatography/tandem mass spectrometry
Ma, Z., Lu, S., Zhou, H., Zhang, S., Wang, Y., & Lin, N. (2020) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8955 · Cited by 15
Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
Denis, M. G., & Bennouna, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s218751 · Cited by 16
The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
Zhao, Z., Li, L., Wang, Z., Duan, J., Bai, H., & Wang, J. (2020) · Journal of Cancer · doi:10.7150/jca.38411 · Cited by 14
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Ponce, S., Bruna, J., Juan, Ó., Castro, R. L., Navarro, A., Granados, A. L. O., Puente, J., Verger, E., Bartolomé, A. G., & Nadal, E. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.017 · Cited by 14
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
Ekman, S., Cselényi, Z., Varrone, A., Jučaitė, A., Martin, H., Schou, M., Johnström, P., Laus, G., Lewensohn, R., Brown, A. P., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13500 · Cited by 13
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
Reale, M. L., Chiari, R., Tiseo, M., Vitiello, F., Barbieri, F., Cortinovis, D. L., Ceresoli, G. L., Finocchiaro, G., Romano, G. D., Piovano, P. L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.006 · Cited by 13
Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer
de Moraes, F. Y., Mansouri, A., Dasgupta, A., Ramotar, M., Kosyak, N., Weiss, J., Laperrière, N., Millar, B., Berlín, A., Conrad, T., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.036 · Cited by 13
Non-small-cell lung cancer: how to manage EGFR-mutated disease
Pecci, F., Cantini, L., Metro, G., Ricciuti, B., Lamberti, G., Farooqı, A. A., & Berardi, R. (2022) · Drugs in Context · doi:10.7573/dic.2022-4-1 · Cited by 12
Management of CNS metastases in patients with EGFR mutation-positive NSCLC
Shetty, V. V., & Suresh Babu, M. C. (2019) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_455_19 · Cited by 13
Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors
O'Kane, G. M., & Leighl, N. B. (2018) · CNS Drugs · doi:10.1007/s40263-018-0526-4 · Cited by 12
Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy
Kim, J. T., Zhang, W., Lopategui, J. R., Vail, E., & Balmanoukian, A. S. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00296 · Cited by 12
Successful Treatment with Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis
Yoshida, H., Ooi, M., & Kim, Y. H. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.023 · Cited by 12
Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding
Passaro, A., Gianoncelli, L., Stati, V., & de Marinis, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.04 · Cited by 13
Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies
Brastianos, P. K., Ippen, F. M., Hafeez, U., & Gan, H. K. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0614 · Cited by 12
Cost‑effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor‑mutated non‑small‑cell lung cancer
Li, W., Qian, L., Li, W., Chen, X., He, H., Tian, H., Zhao, Y., Wang, X., & Cui, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9774 · Cited by 11
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
Stratmann, J., Michels, S. Y. F., Hornetz, S., Christoph, D. C., Sackmann, S., Spengler, W., Bischoff, H. G., Schäfer, M., Alt, J. A., Müller, A. M., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2754-x · Cited by 11
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
Higuchi, T., Oshiro, H., Zhang, Z., Miyake, K., Sugisawa, N., Katsuya, Y., Yamamoto, N., Hayashi, K., Kimura, H. J., Miwa, S., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.01.007 · Cited by 11
Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
Peng, D., Shan, D., Dai, C., Li, J., Wang, Z., Huang, Z., Peng, R., Zhao, P., & Ma, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287466 · Cited by 11
The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival
Erickson, A. W., & Das, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00797 · Cited by 11
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
Novak, J., Salgia, R., West, H., Villalona-Calero, M. A., Sampath, S., Williams, T. M., Villaflor, V. M., Massarelli, E., Pathak, R., Koczywas, M., et al. (2022) · Cancers · doi:10.3390/cancers14163983 · Cited by 9
Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC
Imber, B. S., Sehgal, R. R., Saganty, R., Reiner, A. S., Ilıca, A. T., Miao, E., Li, B. T., Riely, G. J., Yu, H. A., Panageas, K. S., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100607 · Cited by 9
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Eide, I. J. Z., Grut, H., Helland, Å., Ekman, S., Sørensen, J. B., Hansen, K. H., Grønberg, B. H., Cicenas, S., Koivunen, J. P., Mellemgaard, A., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1973092 · Cited by 9
CNS Metastases in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: Impact on Health Resource Utilization
Chooback, N., Lefresne, S., Lau, S. C. M., & Ho, C. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00054 · Cited by 9
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis
O'Kane, G. M., Su, J. S., Tse, B., Tam, V., Tse, T., Lu, L., Borean, M., Tam, E., Labbé, C., Naik, H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0544 · Cited by 10
Self-citation
Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research
Sampat, P. J., Cortese, A., Goodman, A., Ghelani, G. H., Mix, M. D., Graziano, S. L., & Basnet, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1411432 · Cited by 9
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
Chen, W., Miao, J., Wang, Y., Xing, W., Xu, X.-M., & Wu, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1212313 · Cited by 9
Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
Passiglia, F., Raez, L. E., & Rolfo, C. D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.92 · Cited by 7
Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases
Soo, R. A., Seto, T., Gray, J. E., Thiel, E., Taylor, A., Sawyer, W., Karimi, P., Marchlewicz, E. H., & Brouillette, M. A. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00272-5 · Cited by 8
Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice
Fong, C. H., Meti, N., Kruser, T. J., Weiss, J., Liu, Z. A., Takami, H., Narita, Y., de Moraes, F. Y., Dasgupta, A., Ong, C. K., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-697 · Cited by 8
Self-citation
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
Wakuda, K., Yamaguchi, H., Kenmotsu, H., Fukuda, M., Takeshita, M., Suetsugu, T., Kirita, K., Ebi, N., Hataji, O., Miura, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06874-6 · Cited by 8
Improving outcomes for brain metastases in EGFR mutated NSCLC
Carlisle, J. W., & Ramalingam, S. S. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.08 · Cited by 7
Clinical factors associated with mortality within three months after radiosurgery of asymptomatic brain metastases from non-small cell lung cancer
Kakusa, B. W., Han, S. S., Aggarwal, S., Liu, B., Li, G., Soltys, S. G., & Gephart, M. H. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03002-0 · Cited by 7
Glioblastoma with novel EGFR mutations ( T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report
Boongird, A., Lekcharoensombat, N., Jinawath, A., Theparee, T., Jittapiromsak, N., Shuangshoti, S., Thorner, P. S., & Teerapakpinyo, C. (2023) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23143 · Cited by 7
Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment
Yang, Y., Liu, Q., Cao, L., Sun, W., Gu, X., Liu, B., Xiao, N., Teng, F., Li, X., Chen, M.-J., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01539-x · Cited by 7
The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
Billena, C., Lobbous, M., Cordova, C. A., Peereboom, D. M., Torres-Trejo, A., Chan, T. A.-T., Murphy, E. S., Chao, S. T., Suh, J. H., & Yu, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1110440 · Cited by 7
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies
Yang, S., Wu, S., Zhao, Y., Chen, G., Zhu, B., Li, X., Wang, K., Shi, J., Cang, S., Yao, W., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107194 · Cited by 7
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
Leonetti, A., Facchinetti, F., & Tiseo, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.69 · Cited by 7
Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan
Yoshida, H., Kim, Y. H., Iwatsubo, S., Sakaguchi, C., Sakamori, Y., Nagai, H., Ozasa, H., Mio, T., & Hirai, T. (2020) · Oncology · doi:10.1159/000506368 · Cited by 7
The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis
Cui, S., Zhang, Y., Liu, L., Li, Y., Zhou, R., Huang, X., Cao, S., Huo, X., & Wang, N. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1357 · Cited by 6
Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature
Ozair, M. Z., Giantini-Larsen, A., Eng, J., & Moss, N. S. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00485 · Cited by 6
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
Patel, S. P., & Patel, J. D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02680-1 · Cited by 6
Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control
Jeon, H., Kwak, M., Kim, S., Yu, H.-Y., Shin, J., & Jung, H. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-65220-z · Cited by 6
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Ahn, M., Han, J., Kim, D., Cho, B. C., Kang, J. H., Kim, S.-W., Yang, J. C., Mitsudomi, T., & Lee, J. S. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.200 · Cited by 6
Self-citation
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
Takeda, M., Shimokawa, M., Nakamura, A., Nosaki, K., Watanabe, Y., Kato, T., Hayakawa, D., Tanaka, H., Takahashi, T., Kogure, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.009 · Cited by 6
Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review
Fallet, V., Matton, L., Schernberg, A., Canellas, A., Cornélis, F., & Cadranel, J. L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1152 · Cited by 6
Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
Ahn, B., Kim, J. H., Pyo, K., Lim, S. M., Hong, M. H., Kim, H. R., & Cho, B. C. (2021) · Cancers · doi:10.3390/cancers13153681 · Cited by 6
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Martinez‐García, M., Servitja, S., Quintela, N. V., Fernández, A. A., Jaime, A. B., de Ibargüen, B. C. S., Barco, S. D., Campelo, R. G., Sarrió, R. G., & Sepúlveda-Sánchez, J. M. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02803-0 · Cited by 6
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
Zhu, Y., Zhang, Y., Hu, X., Wang, M., Wang, H., & Liu, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04177-w · Cited by 6
Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy
Ameku, K., & Higa, M. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/9076168 · Cited by 6
A Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms
Naim, M. J., & Samad, A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128349342250121053445 · Cited by 5
The role of the neurologist in the diagnosis and treatment of brain metastases and carcinomatous meningitis
Pellerino, A., Garbossa, D., Rudà, R., & Soffietti, R. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.03.005 · Cited by 5
Predicting the T790M mutation in non-small cell lung cancer (NSCLC) using brain metastasis MR radiomics: a study with an imbalanced dataset
Wu, W.-F., Lai, K.-M., Chen, C., Wang, B.-C., Shen, C., Chen, K., Chen, K.-Y., Lin, E. C., & Chen, C. (2024) · Discover Oncology · doi:10.1007/s12672-024-01333-1 · Cited by 5
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
Liao, B.-C., Lin, C., & Yang, J. C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472765 · Cited by 5
Self-citation
Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
Gal, O., Dudnik, E., Rotem, O., Finkel, I., Peretz, I., Zer, A., Mandel, J. J., Benouaich‐Amiel, A., Siegal, T., Bar, J., et al. (2020) · Journal of Oncology · doi:10.1155/2020/1980891 · Cited by 4
Prognostic factors after salvage resection for local progression of brain metastases after radiotherapy
Arita, H., Ikawa, T., Kanayama, N., Morimoto, M., Umehara, T., Yoshizawa, H., Kodama, Y., Okita, Y., Kinoshita, M., & Konishi, K. (2025) · Acta Neurochirurgica · doi:10.1007/s00701-025-06578-5 · Cited by 4
[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].
Zhao, Z., Ni, Y., Li, L., & Xin, T. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.103.02 · Cited by 4
Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
Almeldin, D. S., Malhotra, J. D., Patel, M. M., Aisner, J., & Jabbour, S. K. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1485 · Cited by 3
Treatment options for EGFR mutation-positive NSCLC patients with leptomeningeal metastases after third-generation TKI resistance: a retrospective real-world study
Yun, W., Liu, A., Wen, J., Zhao, K., & Meng, X. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251403396 · Cited by 3
Improvements in the Synthesis of the Third‐Generation EGFR Inhibitor Osimertinib
Voulgari, P., Alivertis, D., & Skobridis, K. (2021) · Helvetica Chimica Acta · doi:10.1002/hlca.202100066 · Cited by 3
Alternating Administration of Osimertinib for Leptomeningitis and Docetaxel Plus Ramucirumab for Lung Adenocarcinoma Resistant to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Tomizawa, H., Mouri, A., Mikoshiba, S., Tsukamoto, K., Abe, Y., Oda, M., Tsuchiya, M., Yamana, T., Suhara, K., & Kamimura, M. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4427-24 · Cited by 3
Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics
Tang, X., Li, Y., Qian, W., Han, P., Yan, W., & Yang, Z. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1399983 · Cited by 3
The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis
Zhang, L., Ren, H., Wu, Q., Wu, Y.-J., & Song, X. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00669-2 · Cited by 3
Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer
Yang, N., Li, C., Han, X., Feng, Z., Qiu, F., & Han, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12034 · Cited by 3
The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
Spagnuolo, A., Muto, M., Monaco, F., Colantuoni, G., & Gridelli, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.24 · Cited by 3
First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
Ricciuti, B., & Chiari, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.06 · Cited by 3
High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
Pan, Y., Li, M., Yu, M., Chen, J., Yu, H., Liu, K., & Chen, L. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102500 · Cited by 2
Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status
Liao, J., Huang, Y., Gan, J., Pang, L., Ali, W. A. S., Yang, Y., Chen, L., Zhang, L., & Fang, W. (2022) · Cancer Control · doi:10.1177/10732748221081360 · Cited by 2
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
Wakuda, K., Yamaguchi, H., Kenmotsu, H., Fukuda, M., Ito, K., Tsuchiya‐Kawano, Y., Tanaka, K., Harada, T., Nakatani, Y., Miura, S., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100587 · Cited by 2
Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
Quintero, N. E. L., González-Hoyos, D., Yepes, A., Herrera, D. A., Peláez, S., Caicedo-Zamudio, C., Blanco-Daza, E., & López, J. C. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/1939703 · Cited by 2
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Vicente‐Baz, D., Paredes, A., Morán, T., Massutí, B., Reguart, N., Alvarez, R. M., Insa, A., Juan, Ó., Artal, A., Esteban, E., et al. (2020) · Revista Española de Patología · doi:10.1016/j.patol.2019.11.002 · Cited by 2
Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Qi, Y., Hou, Y., & Qi, L.-C. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820940426 · Cited by 2
Real-world Management Patterns in EGFR -mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece
Lampaki, S., Mountzios, G., Georgoulias, V., Rapti, A., Xanthakis, I., Baka, S., Mavroudis, D., Samantas, E., Athanasiadis, E., Zagouri, F., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0386 · Cited by 2
Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study
Płużański, A., Bryl, M., Chmielewska, I., Czyżewicz, G., Luboch-Kowal, J., Wrona, A., Samborska, A., & Krzakowski, M. J. (2023) · Cancers · doi:10.3390/cancers15051581 · Cited by 2
Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report
Liu, Z., Song, P., Zhou, L., Ji, D., Shen, H., Dong, H., & Feng, X. (2023) · Cancer Management and Research · doi:10.2147/cmar.s412199 · Cited by 2
Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland
Knetki‐Wróblewska, M., Kowalski, D. M., Czyżewicz, G., Bryl, M., Wrona, A., Dziadziuszko, R., Kieszko, R., Milanowski, J., Świniuch, D., Ramlau, R., et al. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2020.0130 · Cited by 3
Treatment of Leptomeningeal Metastases
Rhun, É. L., & Weller, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-23417-1_24 · Cited by 2
Intratumoral Resident Microbes Directly Participate in Resistance to EGFR-TKI Targeted Drug Therapy through Metabolism in NSCLCPreprint
Wang, H., Zhang, J., Zhang, J., Hou, W., Zhou, J., Li, M., Liu, X., Li, Y., Fu, F., Tian, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.12.642829 · Cited by 2

Authors: Goss, G., Tsai, C.-M., Shepherd, F. A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., Cantarini, M., Johnson, M., Mitsudomi, T., Jänne, P. A., & Yang, J. C.-H.
Affiliations: University of Ottawa (CA)
Taipei Veterans General Hospital (TW)
University Health Network (CA)
Samsung Medical Center (KR)
Moores Cancer Center (US)
Azienda Ospedaliera di Perugia (IT)
Vall d'Hebron Institute of Oncology (ES)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
AstraZeneca (United Kingdom) (GB)
Kindai University (JP)
National Taiwan University Hospital (TW)
Corresponding author: Goss, G.
ORCID: Goss, G.
Tsai, C.-M.
Shepherd, F.A.
Ahn, M.-J.
Bazhenova, L.
Crinò, L.
Felip, E.
Morabito, A.
Hodge, R.
Cantarini, M.
Johnson, M.
Mitsudomi, T.
Yang, J.C.-H.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2018-03
Volume: 29
Issue: 3
Pages: 687-693
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdx820
OpenAlex: W2776194348
Cited by: 247
References: 27
Citations by year: 2026: 5 · 2025: 12 · 2024: 17 · 2023: 32 · 2022: 25 · 2021: 35 · 2020: 30 · 2019: 40 · 2018: 45
FWCI: 27.37
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 613 d)
Locations: Annals of Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: osimertinib, central nervous system metastasis, disease control rate, progression-free survival, EGFR tyrosine kinase inhibitors, brain metastases, EGFR mutation, targeted therapy, safety profile, subgroup analysis
MeSH terms: Progression-Free Survival, Acrylamides, Adult, Aged, Aniline Compounds, Antineoplastic Agents, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Piperazines, Pyrimidines, Central Nervous System Neoplasms, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks